MetaCap

NeuroSense Therapeutics (NRSN) vs XTL Biopharmaceuticals (XTLB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

XTL Biopharmaceuticals is the larger company by market cap ($3.4 million vs $3.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NRSN-66.49%XTLB-30.81%
+5%-32%-70%
Oct 7, 20261 yearNov 20, 2026
NRSN-65.03%XTLB-30.81%
+5%-32%-68%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NRSN versus XTLB key metrics
MetricNRSNXTLB
Share price$1.28$1.37
Market cap$3.19M$3.37M
1-day change+1.59%-5.84%
EPS (TTM)$-47.10$-0.36
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$451.00K
Net income (latest FY)$-11.13M$-1.03M
Gross margin—0.67%
Operating margin—-481.60%
Net margin—-227.72%
52-week high$24.80$5.64
52-week low$1.10$1.37
Distance from 52-week high-94.84%-75.71%
Analyst consensusstrong_buy—
Avg. price target upside+7503.91%—
Average volume31.57K6.58K
Shares outstanding2.49M2.46M
Employees174
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About NeuroSense Therapeutics

NRSN stock →

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

About XTL Biopharmaceuticals

XTLB stock →

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

NRSN vs XTLB FAQ

Which is bigger, NeuroSense Therapeutics or XTL Biopharmaceuticals?

XTL Biopharmaceuticals (XTLB) is larger, with a market capitalization of $3.37M compared with $3.19M for NeuroSense Therapeutics (NRSN).

Are NeuroSense Therapeutics and XTL Biopharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons